In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.

I believe we are about to do it again with this new AI project called Stargate

Trent A. Basarsky net worth and biography

Trent Basarsky Biography and Net Worth

VP of 908 Devices

Dr. Trent Basarsky is the Vice President of our Commercial business. Trent is a marketing and business executive with more than 20 years of experience in the life sciences sector. Prior to joining 908 Devices, Trent was the Chief Business Officer at Zephyrus Biosciences, the developers of a single cell western platform, which was acquired by BioTechne in 2016. Previously Trent was the VP of Corporate Development at ProteinSimple, a company focused on protein analysis instrumentation, where his responsibilities in corporate development, marketing and intellectual property helped grow the company to over $55M in revenue prior to the successful sale of the company for $300M. Trent served as the Director of Corporate Development at Codexis, a cleantech company focused on next-generation biofuels and pharmaceutical manufacturing. Before joining Codexis, he was Director of Corporate Development at Molecular Devices and helped grow the business to more than $180M prior to the sale of the company for over $600M. He also held positions in marketing, product management, business development and intellectual property at Axon Instruments, which was acquired by Molecular Devices. Trent holds a Ph.D. in Neuroscience from Iowa State University, a B.Sc. in Zoology from the University of Alberta, and is a registered patent agent. He enjoys endurance mountain bike racing, playing competitive hockey, and golf.

What is Trent A. Basarsky's net worth?: The estimated net worth of Trent A. Basarsky is at least $207,000.00 as of April 12th, 2022. Dr. Basarsky owns 75,000 shares of 908 Devices stock worth more than $207,000 as of November 21st. This net worth evaluation does not reflect any other investments that Dr. Basarsky may own. Learn More about Trent A. Basarsky's net worth.
How do I contact Trent A. Basarsky?: The corporate mailing address for Dr. Basarsky and other 908 Devices executives is , , . 908 Devices can also be reached via phone at 857-254-1500 and via email at [email protected]. Learn More on Trent A. Basarsky's contact information.
Has Trent A. Basarsky been buying or selling shares of 908 Devices?: Trent A. Basarsky has not been actively trading shares of 908 Devices within the last three months. Most recently, Trent A. Basarsky sold 15,000 shares of the business's stock in a transaction on Tuesday, April 12th. The shares were sold at an average price of $19.74, for a transaction totalling $296,100.00. Following the completion of the sale, the vice president now directly owns 75,000 shares of the company's stock, valued at $1,480,500. Learn More on Trent A. Basarsky's trading history.
Who are 908 Devices' active insiders?: 908 Devices' insider roster includes Nicolas Barthelemy (VP), Trent Basarsky (VP), Christopher Brown (CTO), Joseph Griffith, IV (CFO), John Kenneweg (VP), and Kevin Knopp (CEO). Learn More on 908 Devices' active insiders.
Are insiders buying or selling shares of 908 Devices?: In the last year, 908 Devices insiders bought shares 3 times. They purchased a total of 30,000 shares worth more than $178,500.00. In the last year, insiders at the sold shares 6 times. They sold a total of 40,346 shares worth more than $324,982.08. The most recent insider tranaction occured on May, 13th when CEO Kevin J Knopp bought 10,000 shares worth more than $64,200.00. Insiders at 908 Devices own 27.7% of the company. Learn More about insider trades at 908 Devices.
Information on this page was last updated on 5/13/2024.

Trent A. Basarsky Insider Trading History at 908 Devices

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/12/2022	Sell	15,000	$19.74	$296,100.00	75,000
3/14/2022	Sell	15,000	$17.66	$264,900.00
9/23/2021	Sell	6,000	$37.70	$226,200.00
8/27/2021	Sell	2,003	$34.96	$70,024.88
8/24/2021	Sell	10,078	$34.95	$352,226.10
7/23/2021	Sell	21,000	$32.25	$677,250.00	47,000

Trent A. Basarsky Buying and Selling Activity at 908 Devices

908 Devices Company Overview

908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling. Its products also comprise Maven and Trace C2, an online device for bioprocess monitoring and control; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. The company operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of the Americas. 908 Devices Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $2.76

$2.52

$2.79

50 Day Range

MA: $3.36

$2.34

$3.91

2 Week Range

Now: $2.76

$2.19

$12.51

Volume

211,392 shs

Average Volume

208,812 shs

Market Capitalization

$96.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.98

Bill Gates’s Next Big AI Bet: Stargate

From Brownstone Research | Ad